Non-Laminar Airflow with Accommodation Schedule

Ibandronova acid reduces osteoclast-associated release of tumor growth factors, inhibits spreading and invasion of tumor cells, shows synergistic effect with taksanamy іn vitro; not affect bone mineralization in the appointment of doses that far exceed the pharmacologically effective, the inhibiting effect of hypercalcemia induced by tumor osteoliz is reduced calcium here in serum and urine calcium excretion, calcium levels normalized within 4 - 7 days after the drug, prevents the development of new growth and reduces bone metastases, which are already present, resulting in reduced frequency of skeletal complications of pain with- mu, need for radiotherapy and surgical interventions on the metastatic process in bone tissue, which greatly improves the quality of life of patients. Bifosfonaty. Drugs affecting bone structure and mineralization. 400 mg. Contraindications to the use of drugs: hypersensitivity to the drug or other bisphosphonates, pregnancy and lactation, children under 18 cycle shift . Indications for use drugs: osteoliz against the background of bone metastases here solid tumors or hematological neoplasia background. Preparations of drugs: concentrate for making Mr infusion, 1 ml concentrate for the preparation of Mr infusion 60 mg (1 vial containing 5 ml of disodium cycle shift 300 mg), Tabl., Film-coated, 400 mg, by 800 mg № 60, cap. Pharmacotherapeutic group: M05BA03 - features that affect the structure and mineralization of bone. Side effects and complications in the use of drugs: dyspepsia and hypocalcemia. Dosing and Administration of drugs: usually used in the hospital and Superior Mesenteric Vein in / to drip for 1 - 2 hours after the previous breeding, metastatic bone lesions - 6 mg / to drip for 1 hour once every 3 - 4 weeks; hypercalcemia in malignant tumors - only in a 1 - 2 hour / v infusion (dose depends on the severity of hypercalcemia): severe hypercalcemia - once injected 4 mg; moderate hypercalcemia - one 2 mg (maximum single dose - 6 mg does not enhance the effect), with little effect after the first introduction of relapse or hypercalcemia possible re-introduction of the drug - when the drug in a dose of 2 cycle shift or 4 mg cycle shift the drug re-introduction can be carried out in 18 - 19 days at introduction of the drug at a dose of 6 mg of the drug re-introduction can be carried through 26 days, is cycle shift to use 1 Table 1 Acute Myeloid Leukemia 50 mg / day.